Page last updated: 2024-09-04

moxifloxacin and Corneal Endothelial Cell Damage

moxifloxacin has been researched along with Corneal Endothelial Cell Damage in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Benetz, BA; Chang, DF; Gardner, S; Lass, JH; Menegay, HJ; OʼBrien, RC; Prajna, NV; Rajendrababu, S; Rhee, DJ; Shekar, M; Szczotka-Flynn, LB	1
Chuck, RS; Kim, M; Park, CY; Park, JH	1
Alves, M; Assis Filho, HL; Cardoso da Silva, I; Cavalcanti Lira, RP; Dias Freire, LM; Ferreira, BG; Leite Arieta, CE; Martini, AAF; Melega, MV; Pedreira Chaves, FR; Reis, RD	1

Trials

2 trial(s) available for moxifloxacin and Corneal Endothelial Cell Damage

Article	Year
Comparative corneal endothelial cell toxicity of differing intracameral moxifloxacin doses after phacoemulsification. Journal of cataract and refractive surgery, 2020, Volume: 46, Issue:3 Topics: Aged; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Corneal Endothelial Cell Loss; Double-Blind Method; Endophthalmitis; Endothelium, Corneal; Female; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; No-Observed-Adverse-Effect Level; Phacoemulsification; Postoperative Complications; Prospective Studies; Visual Acuity	2020
Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial. Journal of cataract and refractive surgery, 2019, Volume: 45, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Corneal Endothelial Cell Loss; Endophthalmitis; Female; Humans; Incidence; Injections; Intraocular Pressure; Male; Middle Aged; Moxifloxacin; Phacoemulsification; Prospective Studies; Visual Acuity	2019

Article

Year

Comparative corneal endothelial cell toxicity of differing intracameral moxifloxacin doses after phacoemulsification.

Journal of cataract and refractive surgery, 2020, Volume: 46, Issue:3

Topics: Aged; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Corneal Endothelial Cell Loss; Double-Blind Method; Endophthalmitis; Endothelium, Corneal; Female; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; No-Observed-Adverse-Effect Level; Phacoemulsification; Postoperative Complications; Prospective Studies; Visual Acuity

2020

Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial.

Journal of cataract and refractive surgery, 2019, Volume: 45, Issue:3

Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Corneal Endothelial Cell Loss; Endophthalmitis; Female; Humans; Incidence; Injections; Intraocular Pressure; Male; Middle Aged; Moxifloxacin; Phacoemulsification; Prospective Studies; Visual Acuity

2019

Other Studies

1 other study(ies) available for moxifloxacin and Corneal Endothelial Cell Damage

Article	Year
Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells. Scientific reports, 2021, 03-18, Volume: 11, Issue:1 Topics: Animals; Anti-Bacterial Agents; Apoptosis; Autophagy; Cell Line, Transformed; Cell Survival; Corneal Endothelial Cell Loss; Endothelial Cells; Endothelium, Corneal; Humans; Microscopy, Electron, Transmission; Moxifloxacin; Reactive Oxygen Species; Signal Transduction; Swine	2021

Article

Year

Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.

Scientific reports, 2021, 03-18, Volume: 11, Issue:1

Topics: Animals; Anti-Bacterial Agents; Apoptosis; Autophagy; Cell Line, Transformed; Cell Survival; Corneal Endothelial Cell Loss; Endothelial Cells; Endothelium, Corneal; Humans; Microscopy, Electron, Transmission; Moxifloxacin; Reactive Oxygen Species; Signal Transduction; Swine

2021